Arrowhead Pharmaceuticals (ARWR) vs Ligand Pharmaceuticals (LGND)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ligand Pharmaceuticals (LGND) has outperformed Arrowhead Pharmaceuticals (ARWR) over the past year, gaining 44.0% versus a gain of 2.3%. Over five years, LGND leads with a +193.2% price change compared with -42.6% for ARWR. Arrowhead Pharmaceuticals is the larger company by market cap ($5.85 billion vs $5.74 billion), about 1.0 times the size, while Ligand Pharmaceuticals is growing revenue faster (+60.4% vs -45.6%).
Ligand Pharmaceuticals converts more of its revenue into profit, with a net margin of 46.4% versus -160.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARWR | LGND |
|---|---|---|
| Share price | $41.37 | $286.85 |
| Market cap | $5.85B | $5.74B |
| 1-day change | -5.22% | -0.03% |
| YTD return | -37.69% | +51.72% |
| 1-year return | +2.27% | +43.98% |
| 5-year return | -42.56% | +193.16% |
| P/E ratio (TTM) | — | 115.20 |
| Forward P/E | — | 24.00 |
| EPS (TTM) | $-5.11 | $2.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $450.82M | $268.09M |
| Revenue growth (YoY) | -45.65% | +60.40% |
| Net income (latest FY) | $-724.21M | $124.45M |
| Operating margin | -156.86% | 15.29% |
| Net margin | -160.64% | 46.42% |
| 52-week high | $95.49 | $326.63 |
| 52-week low | $40.43 | $175.89 |
| Distance from 52-week high | -56.68% | -12.18% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +156.39% | +25.94% |
| Average volume | 2.08M | 230.79K |
| Shares outstanding | 141.37M | 20.00M |
| Employees | 1,062 | 47 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LGND has outperformed ARWR by 41.7 percentage points over the past year.
- Ligand Pharmaceuticals is more profitable, keeping 46.4 cents of every revenue dollar as net income versus -160.6 cents for Arrowhead Pharmaceuticals.
- Ligand Pharmaceuticals grew revenue faster in its latest fiscal year (+60.40% vs -45.65%).
About Arrowhead Pharmaceuticals
ARWR stock →Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,062 employees
About Ligand Pharmaceuticals
LGND stock →Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees
ARWR vs LGND FAQ
Which is bigger, Arrowhead Pharmaceuticals or Ligand Pharmaceuticals?
Arrowhead Pharmaceuticals (ARWR) is larger, with a market capitalization of $5.85B compared with $5.74B for Ligand Pharmaceuticals (LGND).
Which stock has performed better over the past year, ARWR or LGND?
LGND returned +43.98% over the past 12 months, compared with +2.27% for ARWR (price return, excluding dividends). Past performance does not predict future results.
Are Arrowhead Pharmaceuticals and Ligand Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.